Nuance Pharma Announces Dosing of First Patient in ENHANCE – China Phase III Trial for Chronic Obstructive Pulmonary Disease (“COPD”)

Nuance Pharma announces dosing of first patient in the ENHANCE – China Phase III Trial for the maintenance treatment of chronic obstructive pulmonary disease of its novel solution Ensifentrine in mainland China.